Company Analysis
Sign in

Prothena Corporation plc (PRTA)

Nasdaq: PRTA · Pharmaceutical Preparations · Dublin 2, IE · filing with the SEC since 2012
Full chart Alerts Compare
Grade5.0
◀ Past 6.7● Present 5.8▶ Future 3.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

68 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Prothena Corporation plc’s names, not what it holds today.

Patents granted
68
68 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 8 in 2024 and 3 in 2023
Applications published
128
12 of them in 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals18
Biotechnology9
Analysis of biological materials2
Measurement1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Prothena Biosciences Limited a subsidiary
IE, as the owner printed on each patent
59 granted
42 published
PROTHENA BIOSCIENCES LIMITED a subsidiary
named as the applicant on its applications, in IE. 2 more under the same name are not counted (printed in IS, printed in IM)
0 granted
68 published
OTHAIR PROTHENA LIMITED a subsidiary
named as the applicant on its applications, in IE
0 granted
18 published
OTHAIR PROTHENA LIMITED a subsidiary
IE, as the owner printed on each patent
9 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,479,910Antibodies recognizing tauBiotechnologyProthena Biosciences Limited
Oct 7, 202512,435,129Anti-Aβ antibodiesBiotechnologyOTHAIR PROTHENA LIMITED
Mar 11, 202512,247,056Multi-epitope vaccine for the treatment of Alzheimer's diseasePharmaceuticalsOTHAIR PROTHENA LIMITED
Mar 4, 202512,240,894Methods of treating AL amyloidosisPharmaceuticalsProthena Biosciences Limited
Jan 14, 202512,195,525Tau immunotherapyPharmaceuticalsProthena Biosciences Limited
Sep 10, 202412,084,491Treatment of Parkinson's diseasePharmaceuticalsProthena Biosciences Limited
Jul 30, 202412,049,498Humanized antibodies recognizing sortilinBiotechnologyProthena Biosciences Limited
Jul 30, 202412,049,497Antibodies recognizing sortilinBiotechnologyProthena Biosciences Limited
Apr 23, 202411,965,005Multi-epitope vaccine for the treatment of Alzheimer's diseasePharmaceuticalsOTHAIR PROTHENA LIMITED
Apr 16, 202411,958,896Antibodies recognizing tauBiotechnologyProthena Biosciences Limited
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0345418METHODS OF TREATING AL AMYLOIDOSISPharmaceuticalsPROTHENA BIOSCIENCES LIMITED
Sep 11, 20252025/0282838Multi-Epitope Vaccine for the Treatment of Alzheimer's DiseasePharmaceuticalsOTHAIR PROTHENA LIMITED
Aug 28, 20252025/0268999Treatment and Prophylaxis of AmyloidosisPharmaceuticalsPROTHENA BIOSCIENCES LIMITED
Jun 12, 20252025/0188159METHODS OF TREATING AL AMYLOIDOSISPharmaceuticalsProthena Biosciences Limited
Jun 12, 20252025/0188158Treatment of Parkinson's DiseasePharmaceuticalsPROTHENA BIOSCIENCES LIMITED
Jun 12, 20252025/0186567MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASEPharmaceuticalsOTHAIR PROTHENA LIMITED
Jun 5, 20252025/0179161Anti-Abeta AntibodiesBiotechnologyOTHAIR PROTHENA LIMITED
Mar 27, 20252025/0099442COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERSOrganic fine chemistryPROTHENA BIOSCIENCES LIMITED
Mar 13, 20252025/0084153METHODS OF TREATING AL AMYLOIDOSISPharmaceuticalsPROTHENA BIOSCIENCES LIMITED
Mar 6, 20252025/0075007Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune CellsPharmaceuticalsPROTHENA BIOSCIENCES LIMITED
What it applied for, 2024 to 2025: Pharmaceuticals 13 · Biotechnology 4 · Organic fine chemistry 2 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PRTA · research, not advice